Anticytokine strategies for the treatment of septic shock: relevance of animal models.
Heumann
D
D
Division of Infectious Diseases, Department of Internal Medicine, Lausanne, Switzerland.
Glauser
M P
MP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology; D012772:Shock, Septic / Q000628:therapy*; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha